Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Apr;101(4):855-867.
doi: 10.1007/s00277-022-04770-6. Epub 2022 Feb 7.

Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study

Affiliations
Observational Study

Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study

Federica Martella et al. Ann Hematol. 2022 Apr.

Abstract

The frequency of thrombosis in AML has been evaluated only in a few studies and no validated predictive model is currently available. Recently, DIC score was shown to identify patients at higher thrombotic risk. We aimed to evaluate the frequency of thromboembolism in AML patients treated with intensive chemotherapy and to assess the ability of genetic and clinical factors to predict the thrombotic risk. We performed a retrospective observational study including 222 newly diagnosed adult AML (210) and high-risk MDS (12), treated with intensive chemotherapy between January 2013 and February 2020. With a median follow-up of 44 months, we observed 50 thrombotic events (90% were venous, VTE). The prevalence of thrombosis was 22.1% and the 6-months cumulative incidence of thrombosis was 10%. The median time to thrombosis was 84 days and 52% of the events occurred within 100 days from AML diagnosis. Khorana and DIC score failed to stratify patients according to their thrombotic risk. Only history of a thrombotic event (p = 0.043), particularly VTE (p = 0.0053), platelet count above 100 × 109/L at diagnosis (p = 0.036) and active smoking (p = 0.025) significantly and independently increased the risk of thrombosis, the latter particularly of arterial events. AML genetic profile did not affect thrombosis occurrence. Results were confirmed considering only thromboses occurring within day 100 from diagnosis. DIC score at diagnosis, but not thrombosis, was independently associated with reduced survival (p = 0.004). Previous VTE, platelet count above 100 × 109/L and active smoking were the only factors associate with increased thrombotic risk in AML patients treated intensively, but further studies are needed to validate these results.

Keywords: Acute myeloid leukemia; Disseminated intravascular coagulation; Intensive chemotherapy; Khorana score; Thrombosis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Khorana AA (2010) Venous Thromboembolism and Prognosis in Cancer. Thromb Res 125:490–493. https://doi.org/10.1016/j.thromres.2009.12.023 - DOI - PubMed - PMC
    1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism Is a Leading Cause of Death in Cancer Patients Receiving Outpatient Chemotherapy. J Thromb Haemost 5:632–634. https://doi.org/10.1111/j.1538-7836.2007.02374.x - DOI - PubMed
    1. Falanga A, Russo L, Verzeroli C (2013) Mechanisms of Thrombosis in Cancer. Thromb Res 131(Suppl 1):S59-62. https://doi.org/10.1016/S0049-3848(13)70024-0 - DOI - PubMed
    1. Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis. JAMA 293:715–722. https://doi.org/10.1001/jama.293.6.715 - DOI - PubMed
    1. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of Cancer-Associated Venous Thrombosis. Blood 122:1712–1723. https://doi.org/10.1182/blood-2013-04-460121 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources